Cargando…
Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients
Early hepatocellular carcinoma (HCC) diagnosis is challenging. Moreover, for patients with alpha-fetoprotein (AFP)-negative HCC, this challenge is augmented. MicroRNAs (miRs) profiles may serve as potential HCC molecular markers. We aimed to assess plasma homo sapiens—(hsa)-miR-21-5p, hsa-miR-155-5p...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962339/ https://www.ncbi.nlm.nih.gov/pubmed/36834570 http://dx.doi.org/10.3390/ijms24043157 |
_version_ | 1784895980260294656 |
---|---|
author | Eldosoky, Mona A. Hammad, Reham Elmadbouly, Asmaa A. Aglan, Reda Badr Abdel-Hamid, Sherihan G. Alboraie, Mohamed Hassan, Donia Ahmed Shaheen, Mohamed A. Rushdi, Areej Ahmed, Reem M. Abdelbadea, Alzahra Abdelmageed, Neamat A. Elshafei, Ahmed Ali, Elham Abo-Elkheir, Omaima I. Zaky, Samy Hamdy, Nadia M. Lambert, Claude |
author_facet | Eldosoky, Mona A. Hammad, Reham Elmadbouly, Asmaa A. Aglan, Reda Badr Abdel-Hamid, Sherihan G. Alboraie, Mohamed Hassan, Donia Ahmed Shaheen, Mohamed A. Rushdi, Areej Ahmed, Reem M. Abdelbadea, Alzahra Abdelmageed, Neamat A. Elshafei, Ahmed Ali, Elham Abo-Elkheir, Omaima I. Zaky, Samy Hamdy, Nadia M. Lambert, Claude |
author_sort | Eldosoky, Mona A. |
collection | PubMed |
description | Early hepatocellular carcinoma (HCC) diagnosis is challenging. Moreover, for patients with alpha-fetoprotein (AFP)-negative HCC, this challenge is augmented. MicroRNAs (miRs) profiles may serve as potential HCC molecular markers. We aimed to assess plasma homo sapiens—(hsa)-miR-21-5p, hsa-miR-155-5p, hsa-miR-192-5p, and hsa-miR-199a-5p—expression levels as a panel of biomarkers for HCC in chronic hepatitis C virus (CHCV) patients with liver cirrhosis (LC), especially AFP-negative HCC cases, as a step toward non-protein coding (nc) RNA precision medicine. Subjects and methods: 79 patients enrolled with CHCV infection with LC, subclassified into an LC group without HCC (n = 40) and LC with HCC (n = 39). Real-time quantitative PCR was used to measure plasma hsa-miR-21-5p, hsa-miR-155-5p, hsa-miR-192-5p, and hsa-miR-199a-5p. Results: Plasma hsa-miR-21-5p and hsa-miR-155-5p demonstrated significant upregulation, while hsa-miR-199a-5p demonstrated significant downregulation in the HCC group (n = 39) when compared to the LC group (n = 40). hsa-miR-21-5p expression was positively correlated with serum AFP, insulin, and insulin resistance (r = 0.5, p < 0.001, r = 0.334, p = 0.01, and r = 0.303, p = 0.02, respectively). According to the ROC curves, for differentiating HCC from LC, combining AFP with each of hsa-miR-21-5p, hsa-miR-155-5p, and miR199a-5p improved the diagnostic sensitivity to 87%, 82%, and 84%, respectively, vs. 69% for AFP alone, with acceptable specificities of 77.5%, 77.5%, and 80%, respectively, and AUC = 0.89, 0.85, and 0.90, respectively vs. 0.85 for AFP alone. hsa-miR-21-5p/hsa-miR-199a-5p and hsa-miR-155-5p/hsa-miR-199a-5p ratios discriminated HCC from LC at AUC = 0.76 and 0.71, respectively, with sensitivities = 94% and 92% and specificities = 48% and 53%, respectively. Upregulation of plasma hsa-miR-21-5p was considered as an independent risk factor for HCC development [OR = 1.198(1.063–1.329), p = 0.002]. Conclusions: Combining each of hsa-miR-21-5p, hsa-miR-155-5p, and hsa-miR-199a-5p with AFP made it possible to identify HCC development in the LC patients’ cohort with higher sensitivity than using AFP alone. hsa-miR-21-5p/hsa-miR-199a-5p and hsa-miR-155-5p/hsa-miR-199a-5p ratios are potential HCC molecular markers for AFP-negative HCC patients. hsa-miR-21-5p was linked, clinically and via in silico proof, to insulin metabolism, inflammation, dyslipidemia, and tumorigenesis in the HCC patients’ group as well as for an upregulated independent risk factor for the emergence of HCC from LC in the CHCV patients. |
format | Online Article Text |
id | pubmed-9962339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99623392023-02-26 Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients Eldosoky, Mona A. Hammad, Reham Elmadbouly, Asmaa A. Aglan, Reda Badr Abdel-Hamid, Sherihan G. Alboraie, Mohamed Hassan, Donia Ahmed Shaheen, Mohamed A. Rushdi, Areej Ahmed, Reem M. Abdelbadea, Alzahra Abdelmageed, Neamat A. Elshafei, Ahmed Ali, Elham Abo-Elkheir, Omaima I. Zaky, Samy Hamdy, Nadia M. Lambert, Claude Int J Mol Sci Article Early hepatocellular carcinoma (HCC) diagnosis is challenging. Moreover, for patients with alpha-fetoprotein (AFP)-negative HCC, this challenge is augmented. MicroRNAs (miRs) profiles may serve as potential HCC molecular markers. We aimed to assess plasma homo sapiens—(hsa)-miR-21-5p, hsa-miR-155-5p, hsa-miR-192-5p, and hsa-miR-199a-5p—expression levels as a panel of biomarkers for HCC in chronic hepatitis C virus (CHCV) patients with liver cirrhosis (LC), especially AFP-negative HCC cases, as a step toward non-protein coding (nc) RNA precision medicine. Subjects and methods: 79 patients enrolled with CHCV infection with LC, subclassified into an LC group without HCC (n = 40) and LC with HCC (n = 39). Real-time quantitative PCR was used to measure plasma hsa-miR-21-5p, hsa-miR-155-5p, hsa-miR-192-5p, and hsa-miR-199a-5p. Results: Plasma hsa-miR-21-5p and hsa-miR-155-5p demonstrated significant upregulation, while hsa-miR-199a-5p demonstrated significant downregulation in the HCC group (n = 39) when compared to the LC group (n = 40). hsa-miR-21-5p expression was positively correlated with serum AFP, insulin, and insulin resistance (r = 0.5, p < 0.001, r = 0.334, p = 0.01, and r = 0.303, p = 0.02, respectively). According to the ROC curves, for differentiating HCC from LC, combining AFP with each of hsa-miR-21-5p, hsa-miR-155-5p, and miR199a-5p improved the diagnostic sensitivity to 87%, 82%, and 84%, respectively, vs. 69% for AFP alone, with acceptable specificities of 77.5%, 77.5%, and 80%, respectively, and AUC = 0.89, 0.85, and 0.90, respectively vs. 0.85 for AFP alone. hsa-miR-21-5p/hsa-miR-199a-5p and hsa-miR-155-5p/hsa-miR-199a-5p ratios discriminated HCC from LC at AUC = 0.76 and 0.71, respectively, with sensitivities = 94% and 92% and specificities = 48% and 53%, respectively. Upregulation of plasma hsa-miR-21-5p was considered as an independent risk factor for HCC development [OR = 1.198(1.063–1.329), p = 0.002]. Conclusions: Combining each of hsa-miR-21-5p, hsa-miR-155-5p, and hsa-miR-199a-5p with AFP made it possible to identify HCC development in the LC patients’ cohort with higher sensitivity than using AFP alone. hsa-miR-21-5p/hsa-miR-199a-5p and hsa-miR-155-5p/hsa-miR-199a-5p ratios are potential HCC molecular markers for AFP-negative HCC patients. hsa-miR-21-5p was linked, clinically and via in silico proof, to insulin metabolism, inflammation, dyslipidemia, and tumorigenesis in the HCC patients’ group as well as for an upregulated independent risk factor for the emergence of HCC from LC in the CHCV patients. MDPI 2023-02-05 /pmc/articles/PMC9962339/ /pubmed/36834570 http://dx.doi.org/10.3390/ijms24043157 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Eldosoky, Mona A. Hammad, Reham Elmadbouly, Asmaa A. Aglan, Reda Badr Abdel-Hamid, Sherihan G. Alboraie, Mohamed Hassan, Donia Ahmed Shaheen, Mohamed A. Rushdi, Areej Ahmed, Reem M. Abdelbadea, Alzahra Abdelmageed, Neamat A. Elshafei, Ahmed Ali, Elham Abo-Elkheir, Omaima I. Zaky, Samy Hamdy, Nadia M. Lambert, Claude Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients |
title | Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients |
title_full | Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients |
title_fullStr | Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients |
title_full_unstemmed | Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients |
title_short | Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients |
title_sort | diagnostic significance of hsa-mir-21-5p, hsa-mir-192-5p, hsa-mir-155-5p, hsa-mir-199a-5p panel and ratios in hepatocellular carcinoma on top of liver cirrhosis in hcv-infected patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962339/ https://www.ncbi.nlm.nih.gov/pubmed/36834570 http://dx.doi.org/10.3390/ijms24043157 |
work_keys_str_mv | AT eldosokymonaa diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT hammadreham diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT elmadboulyasmaaa diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT aglanredabadr diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT abdelhamidsherihang diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT alboraiemohamed diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT hassandoniaahmed diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT shaheenmohameda diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT rushdiareej diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT ahmedreemm diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT abdelbadeaalzahra diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT abdelmageedneamata diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT elshafeiahmed diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT alielham diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT aboelkheiromaimai diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT zakysamy diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT hamdynadiam diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients AT lambertclaude diagnosticsignificanceofhsamir215phsamir1925phsamir1555phsamir199a5ppanelandratiosinhepatocellularcarcinomaontopoflivercirrhosisinhcvinfectedpatients |